Riluzole- and resveratrol-induced delay of retinal ganglion cell death in an experimental model of glaucoma

Current Eye Research

Volumn 41, Issue 1, 2016, Pages 59-69

  Pirhan, Dilara ^a   Yüksel, Nurşen ^a   Emre, Esra ^a   Cengiz, Abdulkadir ^b   Kürşat Yildiz, Demir ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Technical Education Faculty   (Turkey)

Author keywords

Glaucoma; neuroprotection; resveratrol; retinal ganglion cell; riluzole

Indexed keywords

HYALURONIC ACID; RESVERATROL; RILUZOLE; TETRAMETHYLRHODAMINE; ANTIOXIDANT; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DENSITY; GLAUCOMA; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; RAT; RETINA NERVE CELL; ANIMAL; CELL COUNT; CELL SURVIVAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; OCULOPLETHYSMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RETINA GANGLION CELL; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLAUCOMA; INJECTIONS, INTRAPERITONEAL; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; RILUZOLE; STILBENES; TONOMETRY, OCULAR;

EID: 84953349093     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2015.1004719     Document Type: Article

References (65)

1. Bonomi L. Epidemiology of angle-closure glaucoma. Acta Ophthalmol Scand Suppl 2002;236:11-13.
2. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989;107:186-188.
3. Yücel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 2003;22: 465-481.
4. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 2005;46: 175-182.
5. Yamamoto K, Maruyama K, Himori N, Omodaka K, Yokoyama Y, Shiga Y, et al. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci 2014;55:7126-7136.
6. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007;67:725-759.
7. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:191-206.
8. Hains BC, Waxman SG. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Invest Ophthalmol Vis Sci 2005;46: 4164-4169.
9. Springer JE, Azbill RD, Kennedy SE, George J, Geddes JW. Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment. J Neurochem 1997;69: 1592-1600.
10. Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 1997;77:3021-3034.
11. Schwartz G, Fehlings MG. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 2002;137: 177-190.
12. Mozaffarieh M, Grieshaber MC, Orgül S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol 2008;53:479-505.
13. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007;35:1156-1160.
14. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002;958: 439-447.
15. Gao D, Zhang X, Jiang X, Peng Y, HuangW, Cheng G, Song L. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci 2006;78:2564-2570.
16. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience 2009;159: 993-1002.
17. Kiziltepe U, Turan NN, Han U, Ulus AT, Akar F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J Vasc Surg 2004;40: 138-145.
18. Shigematsu S, Ishida S, Hara M, Takahashi N, Yoshimatsu H, Sakata T, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-Activating factor, or oxidants. Free Radic Biol Med 2003;34:810-817.
19. Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 2005;19:840-841.
20. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430:686-689.
21. Chang G, Guo Y, Jia Y, Duan W, Li B, Yu J, Li C. Protective effect of combination of sulforaphane and riluzole on glutamate-mediated excitotoxicity. Biol Pharm Bull 2010; 33:1477-1483.
22. Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 2010;9:305-313.
23. Mimura T, Kaji Y, Noma H, Funatsu H, Okamoto S. The role of SIRT1 in ocular aging. Exp Eye Res 2013;116: 17-26.
24. Kim SH, Park JH, Kim YJ, Park KH. The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection. Mol Vis 2013;19:1667-1676.
25. Yáñez M, Galán L, Matás-Guiu J, Vela A, Guerrero A, GarcáAG. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 2011;1423:77-86.
26. Moreno MC, Marcos HJ, Oscar Croxatto J, Sande PH, Campanelli J, Jaliffa CO, et al. A new experimental model of glaucoma in rats through intracameral injections of hyaluronic acid. Exp Eye Res 2005;81:71-80.
27. Moore CG, Johnson EC, Morrison JC. Circadian rhythm of intraocular pressure in the rat. Curr Eye Res 1996;15: 185-191.
28. Drouyer E, Dkhissi-Benyahya O, Chiquet C, WoldeMussie E, Ruiz G, Wheeler LA, et al. Glaucoma alters the circadian timing system. PLoS One 2008;3:e3931.
29. Moore CG, Epley D, Milne ST, Morrison JC. Long-term non-invasive measurement of intraocular pressure in the rat eye. Curr Eye Res 1995;14:711-717.
30. Moore CG, Milne ST, Morrison JC. Noninvasive measurement of rat intraocular pressure with the Tono-Pen. Invest Ophthalmol Vis Sci 1993;34:363-369.
31. Salinas-Navarro M, Jiménez-López M, Valiente-Soriano FJ, Alarcón-Martínez L, Avilés-Trigueros M, Mayor S, et al. Retinal ganglion cell population in adult albino and pigmented mice: a computerized analysis of the entire population and its spatial distribution. Vision Res 2009;49: 637-647.
32. Salinas-Navarro M, Mayor-Torroglosa S, Jiménez-López M, Avilés-Trigueros M, Holmes TM, Lund RD, et al. A computerized analysis of the entire retinal ganglion cell population and its spatial distribution in adult rats. Vision Res 2009;49:115-126.
33. Sellés-Navarro I, Villegas-Pérez MP, Salvador-Silva M, Ruiz-Gómez JM, Vidal-Sanz M. Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals. A quantitative in vivo study. Invest Ophthalmol Vis Sci 1996;37:2002-2014.
34. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-2855.
35. WoldeMussie E, Wijono M, Ruiz G. Muller cell response to laser-induced increase in intraocular pressure in rats. Glia 2004;47:109-119.
36. Blair M, Pease ME, Hammond J, Valenta D, Kielczewski J, Levkovitch-Verbin H, Quigley H. Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci 2005;46: 884-890.
37. Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005;18:383-395.
38. Leikert JF, Räthel TR, Wohlfart P, Cheynier V, Vollmar AM, Dirsch VM. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 2002;106: 1614-1617.
39. Fuhrman B, Volkova N, Coleman R, Aviram M. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J Nutr 2005;135:722-728.
40. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006;231:113-122.
41. Rice-Evans CA, Miller NJ, Paganga G. Structure-Antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996;20:933-956.
42. Saito S, Ohashi M, Naito A, Fukaya Y, Suzuki Y, Araie M. Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells. Jpn J Ophthalmol 2005;49:371-376.
43. Lagreze WA, Knorle R, Bach M, Feuerstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998;39: 1063-1066.
44. Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y, et al. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res 2000;70: 475-484.
45. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379.
46. Hubert JP, Delumeau JC, Glowinski J, Prémont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
47. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-d-Aspartate-or veratridineinduced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177:95-99.
48. Vorwerk CK, Zurakowski D, McDermott LM, Mawrin C, Dreyer EB. Effects of axonal injury on ganglion cell survival and glutamate homeostasis. Brain Res Bull 2004; 62:485-490.
49. Ettaiche M, Fillacier K, Widmann C, Heurteaux C, Lazdunski M. Riluzole improves functional recovery after ischemia in the rat retina. Invest Ophthalmol Vis Sci 1999; 40:729-736.
50. Nikolaeva MA, Mukherjee B, Stys PK. Na+-dependent sources of intra-Axonal Ca2+ release in rat optic nerve during in vitro chemical ischemia. J Neurosci 2005;25: 9960-9967.
51. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;233:3-13.
52. Sandalon S, Könnecke B, Levkovitch-Verbin H, Simons M, Hein K, Sättler MB, et al. Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. Exp Eye Res 2013; 115:47-56.
53. Wu Y, Satkunendrarajah K, Teng Y, Chow DS, Buttigieg J, Fehlings MG. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma 2013;15;30: 441-452.
54. Mu X, Azbill RD, Springer JE. Riluzole improves measures of oxidative stress following traumatic spinal cord injury. Brain Res 2000;870:66-72.
55. Liu XQ, Wu BJ, Pan WH, Zhang XM, Liu JH, Chen MM, et al. Resveratrol mitigates rat retinal ischemic injury: the roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. J Ocul Pharmacol Ther 2013;29: 33-40.
56. Luna C, Li G, Liton PB, Qiu J, Epstein DL, Challa P, Gonzalez P. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009;47: 198-204.
57. Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006;137:241-251.
58. Dong W, Li N, Gao D, Zhen H, Zhang X, Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc Surg 2008; 48:709-714.
59. Schwartz GW, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001;94: 245-256.
60. Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, Cakir CO, Kocak A. Comparative neuroprotective effect of sodium channel blokers after experimental spinal cord injury. J Clin Neurosci 2007;14:658-665.
61. Morris-Blanco KC, Cohan CH, Neumann JT, Sick TJ, Perez-Pinzon MA. Protein kinase C epsilon regulates mitochondrial pools of Nampt and NAD following resveratrol and ischemic preconditioning in the rat cortex. J Cereb Blood Flow Metab 2014;34:1024-1032.
62. Benazzouz A, Boraud T, Dubédat P, Boireau A, Stutzmann JM, Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995;284:299-307.
63. Medico M, Nicosia A, Grech M, Onesta M, Sessa G, Rampello L, et al. Riluzole restores motor activity in rats with post-traumatic peripheral neuropathy. Neurosci Lett 2004;358:37-40.
64. Ruel J, Wang J, Pujol R, Hameg A, Dib M, Puel JL. Neuroprotective effect of riluzole in acute noise-induced hearing loss. Neuroreport 2005;16:1087-1090.
65. Abdul Y, Akhter N, Husain S. Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model. Invest Ophthalmol Vis Sci 2013;54:1816-1828.